Telix Pharmaceuticals (TLX AU) aims to raise at least US$100m in its US ADS listing. The bookrunners on the deal are Jefferies, Morgan Stanley, Truist Securities, and William Blair.
What is covered in the Full Insight:
Deal Background
Past Funding Deals
Recent Performance and Deal Impact
Upcoming Developments
Analysts' Views and Valuation
Boomeranged on Thu, 6 Jun 2024 14:45
Telix Pharmaceuticals has launched its bookbuild to raise US$200m from its US ADR listing. Pricing is scheduled for 13th Jun 2024, after market close. The shares have continued to trade higher, and are now 15.9% higher than when we first published our note on the deal.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.